Share Name Share Symbol Market Type
Compugen Ltd. - Ordinary Shares NASDAQ:CGEN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -$0.0099 -0.28% $3.5401 $3.54 $3.55 $3.58 $3.45 $3.56 52,001 15:46:51

Bristol-Myers, Compugen to Collaborate on Advanced Solid Tumors

11/10/2018 12:50pm

Dow Jones News

Compugen Ltd. - Ordinary Shares (NASDAQ:CGEN)
Historical Stock Chart

1 Month : From Sep 2018 to Oct 2018

Click Here for more Compugen Ltd. - Ordinary Shares Charts.
   By Colin Kellaher 

Bristol-Myers Squibb Co. (BMY) and Compugen Ltd. (CGEN) Thursday said they will evaluate the safety and tolerability of Compugen's COM701 antibody in combination with Bristol-Myers' cancer drug Opdivo in patients with advanced solid tumors.

As part of the collaboration, Bristol-Myers will invest $12 million in Compugen, buying 2.42 million shares of the Israel-based therapeutic discovery and development company at $4.95 apiece. Compugen shares, which closed Wednesday at $3.25, surged 17% to $3.80 in premarket trading Thursday.

The companies said Compugen will sponsor an ongoing two-part Phase 1 trial that includes evaluating the combination of COM701 and Opdivo in four tumor types, including non-small cell lung, ovarian, breast and endometrial cancer. The collaboration is also designed to address potential future combinations, including trials sponsored by Bristol-Myers, the companies said.


Write to Colin Kellaher at


(END) Dow Jones Newswires

October 11, 2018 07:35 ET (11:35 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

1 Year Compugen Ltd. - Ordinary Shares Chart

1 Year Compugen Ltd. - Ordinary Shares Chart

1 Month Compugen Ltd. - Ordinary Shares Chart

1 Month Compugen Ltd. - Ordinary Shares Chart
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V:gb D:20181016 15:03:04